novo nordisk septerna

Order byBest matchMost fresh

Novo Nordisk Inks A Major Obesity Deal

Top News

Impacts

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.

· 15h · on MSN

· 1d · on MSN

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

Fierce Biotech · 1d

Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs

Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases

Under the terms of the agreement, Septerna is eligible to receive around $2.2 billion from Novo Nordisk, including over $200 million in upfront and near-term milestone payments.

· 15h

Ignore The Noise - Novo Nordisk Is A Clear Buy

STAT · 1d

Novo Nordisk strikes deal with Septerna to develop obesity pills

TMCnet1h

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted key business updates and upcoming milestones and reported financial results for the first quarter ended March 31, 2025.

Eli Lilly Shares Tumble After Rival Novo?Nordisk Strikes Major Weight Loss Deal

Meanwhile, Eli Lilly's Zepbound injection has gained traction, prompting both firms to race toward more convenient weight?loss pills. Investors will watch upcoming trial readouts and regulatory decisions closely.